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Reply to Letter to the Editor from Prof. Legemate Regarding "Number needed to treat: analyzing of the effectiveness of thorocoabdominal aortic repair." Eur J Vasc Endovasc Surg 2004:28:154-157.
Prof. Legemate 1 identifies the use of remote historical controls, whose characteristics are divergent in several ways from our population, as a fundamental methodological flaw, which renders our findings 'both misleading and meaningless'. We considered the issues of historicity and match at length before we submitted the abstract, and we debated this point with commentators from the audience in Dublin and with reviewers of the manuscript in the publication process. We freely admit that the match with our cohort is less than ideal, but we reiterate our point that the study of Bickerstaff 2 and colleagues represents the best evidence we will ever have about the natural history of thoracic/thoracoabdominal aortic aneurysm.
Fundamentally, Prof. Legemate's criticism is about quality of evidence, and it is based on the generally accepted evidence-based medicine doctrine that clinical trials represent the ultimate in clinical research evidence. This is generally true, but is not so in this case.
Watchful waiting clinical trials in vascular surgery are different than the kinds of clinical trials that evidence-based guidelines hold in highest esteem. The difference is that the natural history of aortic aneurysms is widely enough understood that equipoise is disrupted when aneurysms reach a certain threshold, and surgical treatment-the treatment being studied-is extended to patients in the nonsurgical group. That is to say, vascular surgery trials are never run out to the bitter end (e.g. Lederle 3 ). Crossover triggers involve aneurysm size and rate of expansion, which have been shown to increase risk of rupture, and the crossovers are used for ethical, rather than scientific, reasons. How have size and rate of expansion been shown to increase risk? By observational natural history studies, such as the one we used for our comparison. Therefore, we have clinical trials-which reside at the top of the evidence hierarchy-that have crossover rules based on 'impure' observational data. It is a peculiar irony that, when we compute number needed to treat using the kind of data that force crossover to surgery in clinical trials, we are taken to task for not using data from clinical trials! 
